Retatrutide Side Effects: A Plain Review of the Trial Results
Most of what the trials recorded as retatrutide side effects sits in the gut. Nausea, diarrhoea, vomiting and constipation lead every safety table, they climb as the dose goes up, and they bunch together in the weeks when the dose is being stepped up. Two other findings stand out. Heart rate rose in a dose-linked way, and phase 3 brought to light a skin-sensation effect known as dysesthesia that phase 2 had not flagged. This page walks through each published study in turn and is honest about the gaps that remain.
Buy Retatrutide Australia Researchers Trust, Backed by Clear Trial Sources
All of the safety evidence on retatrutide traces back to one developer, Eli Lilly, which ran the trials under the research code LY3437943. The compound is one peptide that switches on three receptors at once (GIP, GLP-1 and glucagon). It remains investigational. Because no regulator has approved it, there is none of the post-marketing surveillance that now exists for semaglutide or tirzepatide.
These are the key studies and announcements behind the numbers on this page.
- Jastreboff and colleagues, NEJM 2023, a phase 2 obesity trial. It enrolled 338 adults living with obesity or overweight for 48 weeks and compared once-weekly doses of 1, 4, 8 and 12 mg with placebo.
- Rosenstock and colleagues, The Lancet 2023, a phase 2 type 2 diabetes trial. It followed 281 adults with type 2 diabetes for 36 weeks and used dulaglutide 1.5 mg as the active comparator.
- Phase 2a liver fat substudy, reported by Sanyal et al. in Nature Medicine in 2024. It drew 98 participants with fatty liver disease out of the obesity trial.
- Phase 3 TRIUMPH and TRANSCEND programmes. These cover TRIUMPH-4 in knee osteoarthritis (topline December 2025), TRANSCEND-T2D-1 in type 2 diabetes (published in The Lancet in 2026), TRIUMPH-1 in obesity (topline May 2026), plus TRIUMPH-2 and TRIUMPH-3 (topline July 2026).
A good share of the phase 3 evidence exists only as topline company announcements rather than full peer-reviewed papers. Read those percentages as provisional. For a grounding in the molecule before the safety detail, our explainer covers how retatrutide works and what it is. Retatrutide is for sale in Australia at NovaPep as a research compound only, shipped from local stock with tracked delivery.
Order Retatrutide Online With the Gut Effects in View
Anything that acts on the GLP-1 receptor tends to upset the digestive tract, so it is no surprise that gastrointestinal events top the list in every retatrutide trial to date. The phase 2 obesity study recorded nausea, diarrhoea, vomiting and constipation. Most cases were mild or moderate, they grew more common with higher doses, and they clustered during escalation.
Phase 3 gives the sharpest numbers. Over 80 weeks in TRIUMPH-1, Lilly reported the following rates for the 12 mg dose compared with placebo.
| Adverse event in TRIUMPH-1 | Retatrutide 12 mg | Placebo |
|---|---|---|
| Nausea | 42.4% | 14.8% |
| Diarrhoea | 32.0% | 13.5% |
| Constipation | 26.1% | 10.9% |
| Vomiting | 25.3% | 4.8% |
Rates were lower in TRANSCEND-T2D-1, the 40-week type 2 diabetes study. Nausea occurred in 16.4%, 19.5% and 26.5% of the 4, 9 and 12 mg arms compared with 3.7% on placebo, and vomiting ran from 15.0% to 17.6% compared with 2.2%. Each trial used its own population, length and escalation plan, so the fair comparison is inside a single trial, not between two of them.
Shop Retatrutide for Sale and Understand How Escalation Shaped Tolerability
Escalation was tested head on in the phase 2 obesity study. Its 4 mg and 8 mg arms were each divided, with one group beginning at 2 mg and another beginning at 4 mg. Beginning at 2 mg trimmed the gastrointestinal events to a degree, and that result is the reason phase 3 moved to a stepwise approach. TRANSCEND-T2D-1 is one example, with a reported regimen that opened at 2 mg and rose every four weeks.
We include these details purely as a description of how supervised trials were designed. Nobody should treat them as a schedule. The useful takeaway is a narrow one. Any tolerability figure is heavily shaped by how fast the dose climbed, so a quoted percentage that arrives without its escalation scheme tells you very little.
Buy Retatrutide Online Knowing the Heart Rate and Cardiovascular Picture
Like most GLP-1 based compounds, retatrutide pushes resting heart rate upward. In the phase 2 obesity study the rise tracked the dose, reached its peak at about week 24 and eased off afterwards. Accounts of that trial place the peak increase at roughly 5 to 10 beats per minute in the higher dose groups.
Whether the compound changes cardiovascular outcomes is a different matter, and it has not been settled. TRIUMPH-3 recruited people with obesity and existing cardiovascular disease. Analysts reviewing the July 2026 results pointed to 27 major adverse cardiovascular events on retatrutide compared with 23 on placebo, and warned that the counts were too low to support any conclusion. A purpose-built cardiovascular and kidney outcomes study, TRIUMPH-Outcomes, is still under way, and its Australian sites include The Alfred, Royal North Shore and Fiona Stanley hospitals.
Order Retatrutide Australia Wide and Note the Dysesthesia Signal
In our view this is the most overlooked result in the whole programme. Dysesthesia describes skin sensation that feels altered or unpleasant, for example tingling, burning or heightened sensitivity to touch. Phase 2 did not raise it as a signal. TRIUMPH-4, however, recorded it in 8.8% of the 9 mg group and 20.9% of the 12 mg group, compared with 0.7% on placebo. Most of these events were mild, and most did not cause anyone to stop treatment.
In TRIUMPH-1 about one participant in ten on the top doses reported dysesthesia. TRANSCEND-T2D-1 put the figure at 2.3% to 4.5% in the retatrutide arms, with no cases on placebo. Published data has not yet offered a mechanism. A signal that only shows up once thousands of people are enrolled is a useful reminder of how small phase 2 safety tables really are.
Shop Retatrutide With Dropout and Serious Event Rates in Mind
The share of participants who quit because of adverse events is arguably the most telling single measure of tolerability, since it records people who actually stopped. Here is what each trial reported.
- Phase 2 obesity (48 weeks). Between 6% and 16% of the retatrutide groups discontinued, with none on placebo. Serious adverse events ranged from 0% to 6% on retatrutide against 4% on placebo.
- TRIUMPH-1 (80 weeks). Discontinuation was 4.1%, 6.9% and 11.3% at 4, 9 and 12 mg, compared with 4.9% on placebo.
- TRIUMPH-4 (68 weeks). The figure was 12.2% at 9 mg and 18.2% at 12 mg, compared with 4% on placebo.
- TRANSCEND-T2D-1 (40 weeks). Rates were 2.2%, 4.5% and 5.1% at 4, 9 and 12 mg, compared with 0% on placebo.
Across 48 weeks, the liver fat substudy found no sign of hepatotoxicity, and there was no ketoacidosis even though beta-hydroxybutyrate rose. The programme tells a consistent story. Tolerability gets worse at the highest dose, and dropout at 12 mg is clearly higher than at 4 mg.
Buy Retatrutide Near Me With the Open Safety Questions Understood
So, is retatrutide safe? That question cannot be answered yet, because no regulator has finished assessing it. The list of things still unknown is a long one.
- Long-term side effects. The longest follow-up reaches 104 weeks, and only in a subgroup of TRIUMPH-1. Nobody has studied effects across many years.
- Cancer. Concern about retatrutide and cancer generally stems from the incretin class as a whole. US prescribing information for semaglutide and tirzepatide includes a boxed warning about thyroid C-cell tumours observed in rodents. We could not find any published human cancer signal for retatrutide in the trial data so far, and a 2025 mouse study in npj Metabolic Health and Disease in fact reported slower tumour growth. Trials of this length cannot prove that no signal exists.
- Cardiovascular outcomes. These await TRIUMPH-Outcomes.
- Muscle and lean mass. The type 2 diabetes trial has a published body composition substudy, yet evidence in large obesity groups is still thin.
Australia also faces a supply problem that has nothing to do with the molecule itself. In June 2026 the Victorian Department of Health said six people using unapproved products labelled retatrutide had developed acute liver injury since January, and it named a contaminant as a possible cause. Then in September 2026 the TGA reported on a product sold as retatrutide that was linked to a patient admitted to hospital with a torn oesophagus. Testing found no retatrutide in it at all, only a large dose of undeclared semaglutide. The TGA's position is that retatrutide should not be used outside a clinical trial.
Order Retatrutide Peptide for Laboratory Research With Identity Testing
Those Australian cases are exactly why any lab handling retatrutide needs proof of identity. Semaglutide has a different molecular mass from retatrutide, so a vial holding the wrong compound shows up straight away on mass spectrometry. Every NovaPep lot goes to an independent laboratory for mass spectrometry (identity) and HPLC (purity), and the lot number printed on your vial can be entered in our certificate of analysis lookup. To understand what a sound result looks like, see our guide to reading a peptide COA. When you buy retatrutide online in Australia from us, every 10, 20 or 30 mg vial carries a lot number linked to its mass spectrometry report.
When it comes to making up vials, the retatrutide reconstitution calculator gives the concentration for a given fill and diluent volume, and bacteriostatic water is the standard diluent. Groups studying incretin mechanisms often run a dual agonist such as research tirzepatide in parallel, and our retatrutide and tirzepatide comparison lays out how the two trial safety profiles differ. Order the tirzepatide pen online as a 3 mL research format if your lab runs both side by side.
Shop Identity-Tested Retatrutide for Sale Near Me
Those TGA findings make the best possible case for buying from a supplier that puts its test results on show. Australian labs wanting retatrutide near me have no need for a local shop, because NovaPep keeps the compound in Australian stock and ships online orders to research groups nationwide. Order the lyophilised retatrutide vial in a 10, 20 or 30 mg fill, or pick the 10 mg retatrutide pen if your team prefers to skip reconstitution. Before checkout, pull up the certificate for your specific lot and confirm the measured mass belongs to retatrutide and not semaglutide. Make that one check part of every purchase and a swapped product gets caught long before a vial is opened.
Research use only. NovaPep sells retatrutide to adults 18+ for laboratory research. It is not for administration to people or animals, and nothing on this page is medical or dosing advice.
Retatrutide Side Effects: A Plain Review of the Trial Results FAQ
What side effects of retatrutide come up most often?
In every trial so far the leading side effects have been gastrointestinal, namely nausea, diarrhoea, vomiting and constipation. TRIUMPH-1 recorded nausea in 42.4% of the 12 mg group compared with 14.8% on placebo. Most events were mild to moderate, grew more frequent as the dose rose, and were concentrated in the escalation weeks.
Has retatrutide been shown to be safe?
Safety has not been established, since no regulator, the TGA included, has approved the compound. Phase 2 and phase 3 data point to a profile broadly in line with other incretin drugs, with an added dysesthesia signal at the higher doses. Long-term, cardiovascular outcome and rare-event evidence is still lacking, and the TGA advises against any use outside a clinical trial.
Is there a link between retatrutide and cancer?
We found no human cancer signal for retatrutide in the published trial data, although the trials are too brief to exclude rare or slowly developing effects. Related GLP-1 drugs carry US warnings over thyroid C-cell tumours observed in rodents. A 2025 mouse study reported slower tumour growth with retatrutide, but that finding is preclinical only.
What does retatrutide do to the heart?
In the phase 2 obesity trial, resting heart rate rose with dose, peaked at about week 24 and then fell back. Its effect on heart attack or stroke risk remains unknown. TRIUMPH-3 was too small to settle the question, and the dedicated TRIUMPH-Outcomes trial, which includes Australian hospital sites, has not yet finished.
What is the dysesthesia seen with retatrutide?
Dysesthesia is skin sensation that feels altered or unpleasant, such as tingling, burning or sensitivity to touch. It surfaced in phase 3, where TRIUMPH-4 recorded it in 8.8% of the 9 mg group and 20.9% of the 12 mg group compared with 0.7% on placebo. Most cases were mild and did not make participants stop, and the cause is still unexplained.
Where can I buy retatrutide near me in Australia?
You do not need a local shop. NovaPep stocks retatrutide in Australia and ships online orders to research groups nationwide, offering three vial fills and a ready-made pen. Only buy where an independent identity result is published for your lot, since the TGA has uncovered products labelled retatrutide that held a different drug.